The Journal of family practice
-
Here is key intelligence on the recommended primary series, boosters, breakthrough infection, adverse events, special population vaccination, vaccine myths, and what the future might hold.
-
Any one of the HD-IIV4, aIIV4, or RIV4 vaccines is recommended over the SD-IIV4 options for those ages ≥ 65 years. Flucelvax is now approved for those ages ≥ 6 months.
-
A Multiple patient-specific and provider-perceived factors delay initiation of treatment in patients with hepatitis C. Patient-specific barriers to initiation of treatment for hepatitis C virus (HCV) include age, race, gender, economic status, insurance status, and comorbidities such as HIV coinfection, psychiatric illness, and other psychosocial factors. Provider-perceived patient factors include substance abuse history, older age, psychiatric illness, medical comorbidities, treatment adverse effect risks, and factors that might limit adherence (eg, comprehension level). Study limitations included problems with generalizability of the populations studied and variability in reporting or interpreting data associated with substance or alcohol use disorders (strength of recommendation: B, based on 2 prospective and 5 retrospective cohort studies).
-
These recommendations can help you to identify patients at risk of violence, create an environment where they feel comfortable disclosing their experiences, and help them plan for their safety.